Changes in coverage of IVD tests under the RIHN innovative funding framework in France

France offers several innovative funding schemes that facilitate early market access for medical technologies. One of these schemes relevant to IVD tests is RIHN (Repository of Innovative Procedures outside the Nomenclature of Biology and Anatomopathology). RIHN provides temporary funding for innovative IVD tests until sufficient evidence is available for regular reimbursement (i.e., inclusion in the Nomenclature of Medical Laboratory Procedures, NABM, or Common Classification of Medical Procedures, CCAM). The French National Authority for Health (HAS) evaluates tests on LAHN to decide whether they can be included in the NABM and CCAM.

With the RIHN reform starting in 2023, a new List of Innovative Procedures Outside the Nomenclature (LAHN) was introduced in 2024, combining tests previously funded via the RIHN framework (the List of innovative tests and the Supplementary List of tests no longer considered innovative). 

On December 31, 2025, the Ministry of Health, Family, Autonomy, and People with Disabilities published a Decree, amending the conditions of coverage of innovative tests currently listed in the LAHN. Changes include extending the maximum duration of this transitional listing from five to nine years. Furthermore, the schedule of planned tariff reductions applicable to LAHN tests has been adjusted: a 20% tariff reduction (compared to the 2024 tariffs) remained in force for 2025 only; starting January 1, 2026, the annual rate will be reduced to 10%.

At the same time, the updated LAHN 2026 was released. While the 2026 tariffs are not explicitly listed in the LAHN 2026, the document outlines the maximum tariff values and the maximum duration of exceptional coverage applicable to tests since 2024. It also incorporates all changes made during 2025, including deregistration, HAS evaluations, and inclusions in the NABM and CCAM. 

The 2026 LAHN also introduces one new duplicative code (to which no tariff reduction applies) for the detection of mutations by microsatellite expansion, applicable to certain clinical indications that have been positively assessed by HAS (e.g., Huntington's disease, Friedreich's ataxia, spinocerebellar ataxias). Other changes concern the modification of wording in code descriptions and/or notes to the number of existing codes. 

See the details in French here (Decree), and here (LAHN 2026).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.